simendan has been researched along with Amyotrophic Lateral Sclerosis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carvalho, M; Swash, M | 1 |
| Aho, VV; Al-Chalabi, A; Cudkowicz, M; Garratt, C; Genge, A; Kuoppamäki, M; Maragakis, N; Petri, S; Sarapohja, T; van den Berg, L | 1 |
| Al-Chalabi, A; Heunks, LMA; Papp, Z; Pollesello, P | 1 |
| Aho, VV; Al-Chalabi, A; Hardiman, O; Kuoppamäki, M; Leigh, PN; Ludolph, A; Sarapohja, T; Shaw, P; van den Berg, L | 1 |
1 review(s) available for simendan and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Potential of the Cardiovascular Drug Levosimendan in the Management of Amyotrophic Lateral Sclerosis: An Overview of a Working Hypothesis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Diaphragm; Disease Progression; Humans; Motor Neurons; Muscle Strength; Neuromuscular Agents; Recovery of Function; Respiration; Respiratory Insufficiency; Simendan; Treatment Outcome | 2019 |
1 trial(s) available for simendan and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Phosphodiesterase 3 Inhibitors; Simendan; Treatment Outcome; Vital Capacity | 2019 |
2 other study(ies) available for simendan and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Levosimendan for amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Humans; Simendan | 2021 |
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Administration, Oral; Amyotrophic Lateral Sclerosis; Double-Blind Method; Humans; Simendan; Treatment Outcome | 2021 |